ES2897790T3 - Un agente que aumenta la expresión del agonista asociado a Bcl2 de la muerte celular para el tratamiento del cáncer - Google Patents

Un agente que aumenta la expresión del agonista asociado a Bcl2 de la muerte celular para el tratamiento del cáncer Download PDF

Info

Publication number
ES2897790T3
ES2897790T3 ES18717108T ES18717108T ES2897790T3 ES 2897790 T3 ES2897790 T3 ES 2897790T3 ES 18717108 T ES18717108 T ES 18717108T ES 18717108 T ES18717108 T ES 18717108T ES 2897790 T3 ES2897790 T3 ES 2897790T3
Authority
ES
Spain
Prior art keywords
agent
cancer
pharmaceutical composition
bad
naltrexol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18717108T
Other languages
English (en)
Spanish (es)
Inventor
Angus Dalgleish
Wai Lui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LDN Pharma Ltd
Original Assignee
LDN Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1704910.7A external-priority patent/GB201704910D0/en
Priority claimed from GBGB1718806.1A external-priority patent/GB201718806D0/en
Application filed by LDN Pharma Ltd filed Critical LDN Pharma Ltd
Application granted granted Critical
Publication of ES2897790T3 publication Critical patent/ES2897790T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES18717108T 2017-03-28 2018-03-28 Un agente que aumenta la expresión del agonista asociado a Bcl2 de la muerte celular para el tratamiento del cáncer Active ES2897790T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1704910.7A GB201704910D0 (en) 2017-03-28 2017-03-28 High dose combi I
GBGB1718806.1A GB201718806D0 (en) 2017-11-14 2017-11-14 Breast cancer treatment
PCT/GB2018/050843 WO2018178690A1 (en) 2017-03-28 2018-03-28 An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer

Publications (1)

Publication Number Publication Date
ES2897790T3 true ES2897790T3 (es) 2022-03-02

Family

ID=61952738

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18717108T Active ES2897790T3 (es) 2017-03-28 2018-03-28 Un agente que aumenta la expresión del agonista asociado a Bcl2 de la muerte celular para el tratamiento del cáncer

Country Status (8)

Country Link
EP (1) EP3600433B1 (https=)
JP (2) JP7657590B2 (https=)
KR (2) KR20200072445A (https=)
CN (1) CN111050801B (https=)
AU (1) AU2018244806B2 (https=)
CA (1) CA3083850A1 (https=)
ES (1) ES2897790T3 (https=)
WO (1) WO2018178690A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049375A1 (en) 2000-03-15 2001-12-06 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
US20030144312A1 (en) 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
EP1479381A1 (en) * 2003-05-19 2004-11-24 Euro-Celtique S.A. Pharmaceutical dosage form comprising a solid solution
EP1868593A2 (en) 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
SMT202500474T1 (it) * 2010-12-03 2026-01-12 Nalpropion Pharmaceuticals Llc Aumento della biodisponibilità farmacologica nella terapia con naltrexone
JP2015107918A (ja) 2012-02-14 2015-06-11 国立研究開発法人国立がん研究センター 抗がん剤の作用を増強する医薬組成物、がん治療用キット、診断薬、及びスクリーニング方法
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
WO2016061531A1 (en) * 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression

Also Published As

Publication number Publication date
KR20240125082A (ko) 2024-08-19
CN111050801B (zh) 2023-03-28
CN111050801A (zh) 2020-04-21
EP3600433A1 (en) 2020-02-05
AU2018244806A1 (en) 2019-11-21
CA3083850A1 (en) 2019-10-04
JP2025027084A (ja) 2025-02-26
JP7657590B2 (ja) 2025-04-07
JP2020515649A (ja) 2020-05-28
US20200101066A1 (en) 2020-04-02
KR20200072445A (ko) 2020-06-22
EP3600433B1 (en) 2021-05-05
AU2018244806B2 (en) 2023-12-21
WO2018178690A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
ES2863996T3 (es) Terapia de combinación para el tratamiento del cáncer
ES2952265T3 (es) Terapia combinada que comprende un inhibidor de Raf y trametinib
ES2629067T3 (es) Combinaciones de un conjugado de anticuerpo anti-HER2-fármaco y pertuzumab
Dei et al. Recent advances in the search of BCRP-and dual P-gp/BCRP-based multidrug resistance modulators
ES2663407T3 (es) Métodos para el tratamiento del cáncer de mama
KR101877840B1 (ko) 암 치료용 화합물을 확인하는 방법
KR102615210B1 (ko) 난소암의 치료에 사용되는 티노스타무스틴
US11708391B2 (en) Rapaglutins, novel inhibitors of GLUT and use thereof
JP6620338B2 (ja) 低用量ナルトレキソンによるがん細胞の準備刺激
Patki et al. In vitro assessment of a synergistic combination of gemcitabine and zebularine in pancreatic cancer cells
US11351165B2 (en) Agent that increases the expression of the opioid kappa 1 for the treatment of cancer
WO2020132259A1 (en) Compositions and methods of treating cancers by administering a phenothiazine-related drug that activates protein phosphatase 2a (pp2a)
JP7132848B2 (ja) 癌の治療のための合理的併用療法
US20260091021A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
ES2897790T3 (es) Un agente que aumenta la expresión del agonista asociado a Bcl2 de la muerte celular para el tratamiento del cáncer
US12611405B2 (en) Agent that increases the expression of the BCL2-associated agonist of cell death for the treatment of cancer
US9566334B2 (en) Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
US12358935B2 (en) Targeting redox-active pyridinium cations to mitochondria to inhibit proliferation of drug-resistant cancer cells
Ji et al. 9-Methoxycamptothecin induces proliferating cell nuclear antigen associated factor 15 mediated proliferation inhibition, DNA damage, and apoptosis in melanoma cells
Rey-Caro et al. Emerging molecular mechanisms and leukemic stem cells in chemoresistance of hematologic tumors
WO2021048418A1 (en) Combination therapies comprising bortezomib for the treatment of cholangiocarcinoma
Mühlenberg et al. 211 Effective therapeutic sensitization of gastrointestinal stromal tumors by a BH3 mimetic